GlassScriptPhysician profile
Adrian R Pearson
NPI 1376968313
$7,614.19
in general payments reported to CMS, 2019-2025
29 companies · $1,047 in 2025
The $1,047 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $794 · 2020: $487 · 2021: $1,199 · 2022: $1,677 · 2023: $272 · 2024: $2,138 · 2025: $1,047.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,965 · Travel and Lodging: $1,492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,964.89 |
| Travel and Lodging | $1,492.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,868.48 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Janssen Pharmaceuticals, INC | $754.96 | 2021-2022 | |
| Pfizer INC. | $739.74 | 2019-2025 | |
| Bridgebio Pharma, INC. | $403.40 | 2025 | Attruby |
| Medtronic, INC. | $373.53 | 2021-2025 | Onyx Frontier, Cobalt Dr Mri Surescan, Telescope |
| E.R. Squibb & Sons, L.L.C. | $338.34 | 2021-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $251.17 | 2019-2025 | Wainua |
| Abiomed | $233.09 | 2023-2025 | Impella |
| Boston Scientific Corporation | $220.82 | 2020-2022 | |
| Amgen INC. | $207.34 | 2020-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $204.65 | 2021-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $181.80 | 2021-2024 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.98 | 2021-2025 | Jardiance |
| Astellas Pharma US INC | $133.13 | 2019 | |
| Sanofi-Aventis U.S. LLC | $64.68 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akcea Therapeutics, INC. | $60.49 | 2020-2021 | |
| Medtronic Vascular, INC. | $56.52 | 2019 | |
| Esperion Therapeutics, INC. | $54.15 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $49.78 | 2022-2024 | |
| Alnylam Pharmaceuticals INC. | $47.27 | 2022-2025 | Onpattro |
| Scpharmaceuticals INC. | $34.97 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $30.57 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $26.17 | 2019 | |
| Amarin Pharma, INC. | $25.14 | 2020 | |
| Atricure, INC. | $23.96 | 2022 | |
| Biosense Webster, INC. | $23.94 | 2021 | |
| Lantheus Medical Imaging, INC. | $19.79 | 2022 | |
| Preventice Services, LLC | $19.22 | 2020 | |
| Inspire Medical Systems, INC. | $19.11 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Pearson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.